SANOFI ADR

NASDAQ: SNY (Sanofi)

Kemas kini terakhir: 07 Mar, 9:18PM

59.25

-0.17 (-0.29%)

  • 1H -0.29%
  • 5H 8.48%
  • 1B 2.60%
  • 6B 7.88%
  • Tahun Ke Tarikh 22.95%
  • 1T 28.14%
  • 5T 28.89%
Penutupan Terdahulu 59.42
Buka 59.15
Jumlah Dagangan 3,311,340
Purata Dagangan (3B) 2,554,861
Modal Pasaran 148,550,418,432
Harga / Pendapatan (P/E TTM) 25.00
Harga / Pendapatan (P/E Ke hadapan) 11.29
Harga / Jualan (P/S) 2.66
Harga / Buku (P/B) 1.48
Julat 52 Minggu
45.22 (-23%) — 59.72 (0%)
Tarikh Pendapatan 24 Apr 2025
Hasil Dividen (DY TTM) 6.88%
Margin Keuntungan 12.56%
Margin Operasi (TTM) 13.99%
EPS Cair (TTM) 2.40
Pertumbuhan Hasil Suku Tahunan (YOY) -3.10%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 11.50%
Jumlah Hutang/Ekuiti (D/E MRQ) 23.01%
Nisbah Semasa (MRQ) 1.46
Aliran Tunai Operasi (OCF TTM) 9.08 B
Aliran Tunai Bebas Leveraj (LFCF TTM) -4.94 B
Pulangan Atas Aset (ROA TTM) 4.28%
Pulangan Atas Ekuiti (ROE TTM) 7.30%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Bercampur Menaik
Drug Manufacturers - General (Global) Bercampur Menaik
Stok Sanofi Menaik Menaik

AISkor Stockmoo

0.1
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam NA
Volatiliti Harga -3.0
Purata Bergerak Teknikal 2.5
Osilator Teknikal -0.5
Purata 0.13

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
SNY 149 B 6.88% 25.00 1.48
AZN 230 B 2.26% 30.43 6.19
AMGN 154 B 3.19% 37.88 26.14
GILD 127 B 3.03% 268.87 7.22
GRFS 6 B - 26.84 0.710
BIIB 21 B - 12.64 1.01

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Core
% Dimiliki oleh Institusi 10.59%

Pemilikan

Nama Tarikh Syer Dipegang
Mondrian Investment Partners Ltd 31 Dec 2024 3,453,122
66.0066.0063.0063.0060.0060.0057.0057.0054.0054.00Harga Sasaran MedianQ1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25
Julat 52 Minggu
45.22 (-23%) — 59.72 (0%)
Median 65.00 (9.71%)
Jumlah 1 Pegang
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Goldman Sachs 21 Mar 2025 65.00 (9.70%) Pegang 56.90

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
08 Apr 2025 Pengumuman Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
08 Apr 2025 Pengumuman Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
03 Apr 2025 Pengumuman Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
03 Apr 2025 Pengumuman Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
03 Apr 2025 Pengumuman Sanofi: Information concerning the total number of voting rights and shares - February 2025
28 Mar 2025 Pengumuman Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
28 Mar 2025 Pengumuman Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
28 Mar 2025 Pengumuman Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
28 Mar 2025 Pengumuman Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
26 Mar 2025 Pengumuman Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
26 Mar 2025 Pengumuman Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
25 Mar 2025 Pengumuman Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
25 Mar 2025 Pengumuman Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
24 Mar 2025 Pengumuman Press Release: Availability of the Q1 2025 Aide mémoire
24 Mar 2025 Pengumuman Press Release: Availability of the Q1 2025 Aide mémoire
20 Mar 2025 Pengumuman Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
20 Mar 2025 Pengumuman Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
14 Mar 2025 Pengumuman Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season
08 Mar 2025 Pengumuman Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
08 Mar 2025 Pengumuman Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
05 Mar 2025 Pengumuman Press release: Sanofi successfully prices EUR 1.5 billion of bond issue
05 Mar 2025 Pengumuman Press release: Sanofi successfully prices EUR 1.5 billion of bond issue
25 Feb 2025 Pengumuman Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
25 Feb 2025 Pengumuman Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
22 Feb 2025 Pengumuman Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
22 Feb 2025 Pengumuman Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
22 Feb 2025 Pengumuman Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
19 Feb 2025 Pengumuman Press Release: Sanofi and CD&R sign Opella share purchase agreement
19 Feb 2025 Pengumuman Press Release: Sanofi and CD&R sign Opella share purchase agreement
18 Feb 2025 Pengumuman Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
18 Feb 2025 Pengumuman Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
13 Feb 2025 Pengumuman Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
13 Feb 2025 Pengumuman Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
13 Feb 2025 Pengumuman Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
13 Feb 2025 Pengumuman Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
07 Feb 2025 Pengumuman Press Release: Execution of a share buyback agreement for up to €2 billion
07 Feb 2025 Pengumuman Press Release: Execution of a share buyback agreement for up to €2 billion
07 Feb 2025 Pengumuman Press Release: Execution of a share buyback agreement for up to €2 billion
03 Feb 2025 Pengumuman Press Release: Sanofi announces buy back of shares from L’Oréal
03 Feb 2025 Pengumuman Press Release: Sanofi announces buy back of shares from L’Oréal
31 Jan 2025 Pengumuman Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
31 Jan 2025 Pengumuman Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
30 Jan 2025 Pengumuman Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025
30 Jan 2025 Pengumuman Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025
29 Jan 2025 Pengumuman Sanofi: Information concerning the total number of voting rights and shares - December 2024
22 Jan 2025 Pengumuman Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma
22 Jan 2025 Pengumuman Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma
21 Jan 2025 Pengumuman Press Release: Opella reaches study milestone for Cialis
21 Jan 2025 Pengumuman Press Release: Opella reaches study milestone for Cialis
15 Jan 2025 Pengumuman Sanofi: Information concerning the total number of voting rights and shares – November 2024
Papar semua
Hasil Dividen (DY TTM) 6.88%
Purata Hasil Dividen 5T 4.78%
Nisbah Pembayaran 85.70%
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
09 May 2024 26 Mar 2024 06 Jun 2024 2.037356 Tunai
09 May 2024 26 Mar 2024 06 Jun 2024 2.0369079 Tunai
30 May 2023 - 23 Jun 2023 1.9000852 Tunai
26 May 2022 - 27 Jun 2022 0.2971788 Tunai
04 May 2022 20 Apr 2022 31 May 2022 1.7967514 Tunai
03 May 2021 23 Mar 2021 26 May 2021 1.906064 Tunai
30 Apr 2020 05 Mar 2020 26 May 2020 1.6993994 Tunai
07 May 2019 - 31 May 2019 1.722322 Tunai
09 May 2018 07 Feb 2018 04 Jun 2018 1.860874 Tunai
11 May 2017 16 Feb 2017 07 Jun 2017 1.577088 Tunai
05 May 2016 19 Feb 2016 01 Jun 2016 1.630252 Tunai
06 May 2015 25 Feb 2015 02 Jun 2015 1.618087 Tunai
17 May 2010 12 Feb 2010 14 Jun 2010 1.62732 Tunai
04 Jun 2007 05 Mar 2007 03 Jul 2007 1.14537 Tunai
02 Jun 2006 06 Mar 2006 03 Jul 2006 0.912 Tunai
02 Jun 2005 01 Mar 2005 01 Jul 2005 0.7993 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2024 4.07 2 8.45
2023 1.90 1 3.82
2022 2.09 2 4.32
2021 1.91 1 3.81
2020 1.70 1 3.50
2019 1.72 1 3.43
2018 1.86 1 4.29
2017 1.58 1 3.67
2016 1.63 1 4.03
2015 1.62 1 3.79
2010 1.63 1 5.05
2007 1.15 1 2.52
2006 0.912 1 1.98
2005 0.799 1 1.82
Papar semua
57.4857.4853.9253.9250.3750.3746.8146.8143.2643.26Apr 1Apr 1Apr 2Apr 2Apr 3Apr 3Apr 4Apr 4Apr 7Apr 7Apr 8Apr 8Apr 9Apr 9Apr 10Apr 10

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.5000.5000.0000.000-0.500-0.500-1.000-1.000-1.500-1.500MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda